Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.

The Journal of antimicrobial chemotherapy - 1 Jul 2011

Malet Isabelle, Wirden Marc, Fourati Slim, Armenia Daniele, Masquelier Bernard, Fabeni Lavinia, Sayon Sophie, Katlama Christine, Perno Carlo Federico, Calvez Vincent, Marcelin Anne-Geneviève, Ceccherini-Silberstein Francesca

Abstract excerpt

OBJECTIVES: To compare the frequency of previously in vitro-selected integrase mutations (T124A, T124A/S153F, S153Y, T124A/S153Y and L101I/T124A/S153Y) conferring resistance to S/GSK1349572 between HIV-1 subtype B integrase inhibitor (INI)-naive and raltegravir-treated patients. METHODS: Integrase sequences from 650 INI-naive patients and 84 raltegravir-treated patients were analysed. RESULTS: The T124A mutation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracenes
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 21474479
DOI: 10.1093/jac/dkr152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.PMID 21474479Read ↗

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.Semantic proximity Read ↗

Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients.Semantic proximity Read ↗

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.Semantic proximity Read ↗

Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitorsSemantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.Semantic proximity Read ↗

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.Semantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.Semantic proximity Read ↗

High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.Semantic proximity Read ↗

Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.Semantic proximity Read ↗

Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.